Deglycosylated Human Monoclonal Antibody Against Hpa-1a Prevents Anti-Hpa-1a Alloantibodies Mediated Endothelial Apoptosis

Hevi Wihadmadyatami,Monika Burg-Roederfeld,Silke Werth,Changgeng Ruan,Mingwang Wei,Gregor Bein,Ulrich J. Sachs,Sentot Santoso
DOI: https://doi.org/10.1182/blood.v124.21.464.464
IF: 20.3
2014-01-01
Blood
Abstract:Foetal/neonatal alloimmune thrombocytopenia (FNAIT) is caused by the destruction of fetal platelets by maternal platelet alloantibodies which crossed through the placenta during pregnancy. Alloantibodies (aabs) against Human Platelet Antigen-1a (HPA-1a) residing on the b-subunit of the fibrinogen receptor (alphaIIbbeta3 integrin) on platelets are responsible for intracranial hemorrhage (ICH) in severe FNAIT cases. Recently, we could demonstrate that the deglycosylated mouse mab SZ21 against HPA-1a is able to cross through placenta, and prevents the destruction of platelets in mouse model (Bakchoul et al, Blood 2013). Meanwhile, this mab is humanized as chimeric antibody (mab 813). It is known that the beta3-subunit is abundantly expressed as vitronectin receptor (alphavbeta3 integrin) on endothelial surface. In this study, we sought to investigate the effect of deglycosylated mab 813 (deg-813) towards endothelial function.
What problem does this paper attempt to address?